<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367458</url>
  </required_header>
  <id_info>
    <org_study_id>060197</org_study_id>
    <secondary_id>06-I-0197</secondary_id>
    <nct_id>NCT00367458</nct_id>
    <nct_alias>NCT00923546</nct_alias>
  </id_info>
  <brief_title>Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy</brief_title>
  <acronym>STATIN</acronym>
  <official_title>A Randomized Placebo Controlled Trial of Atorvastatin in HIV Positive Patients Not on Antiretroviral Medications With the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol)
      on the human immunodeficiency virus (HIV). If not treated, HIV infection causes an incurable,
      progressive deficiency in the immune system that leads to death, usually from disease that
      takes advantage of weakened immunity. Previous studies, however, have suggested that if the
      amount of cholesterol in infected cells is reduced, multiplication of HIV is also reduced. In
      this study, researchers will examine the HIV viral loads, that is, amount of the virus in the
      blood. They will evaluate the composition of the strain of the virus that patients carry (HIV
      genotype), response of the immune system to the virus, and how genes may determine the way in
      which the drug may or may not work against the strain of virus. Researchers plan to enroll 22
      participants, anticipating a study to last 30 weeks for each participant.

      Patients ages 18 or older with HIV infection, who are not pregnant or breastfeeding, who do
      not have a known allergy to atorvastatin use, and who have not had a serious illness or
      infection that required hospitalization within the 30 days before entering the study may be
      eligible for this study. They will be assigned to random groups: one that to receive
      atorvastatin and the other to receive a placebo, which has no effect on cholesterol or
      ability of the HIV infection to multiply. Patients will remain in their groups and treatments
      for 8 weeks. At the completion of 8 weeks, no matter the study group, all patients will be
      required to discontinue all study-related medications for 4 weeks. After that period, the
      study assignments will be switched, so that those previously taking the placebo will take
      atorvastatin, and vice versa. The study will proceed for another 8 weeks, followed by a
      period of stopping study-related medications and patients being observed for 4 weeks.
      Throughout the study, patients will have regularly scheduled visits at the clinic. At those
      visits there will be collection of blood samples, assessments of symptoms, physical
      examinations, and questionnaires to complete. Blood tests may require fasting beforehand, and
      blood samples will be used in standard tests, including those regarding the liver, kidneys,
      muscles, blood cells, and pregnancy status. Specialized blood tests will determine viral
      load, effects of the drug on the immune cells, and genetic influence on the drug's
      effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a randomized, double blind, placebo controlled trial designed to study the
      effects of the lipid lowering statin, atorvastatin on HIV-1 viremia.

      Untreated HIV-1 infection results in an incurable, progressive immunodeficiency and death,
      usually from opportunistic infections. Combination antiretroviral therapy (ARV) has been
      successful in suppressing HIV replication and reducing morbidity and mortality. Long term ARV
      therapy is associated with the development of HIV-1 drug resistance, and significant adverse
      side effects including metabolic and cardiovascular complications. Prolonged therapy with
      certain antiretrovirals is associated with increased risk of cardiovascular disease and a
      number of dyslipidemic syndromes, including increased levels of cholesterol, LDL, and
      triglycerides in peripheral blood. New therapeutic strategies to suppress HIV-1 infection are
      essential.

      Previously, in vitro studies suggested that exposure to cholesterol-lowering statins results
      in decreases in HIV-1 replication. The mechanisms of inhibition remain uncertain, but
      possibilities include disrupting membrane trafficking or cytoskeletal processes necessary for
      intracellular transport of viral proteins, or altering cellular activation state necessary
      for viral gene expression. Initial in vivo studies of the effects of statins on HIV-1 have
      been largely anecdotal in nature and have yielded conflicting results. Although statin
      therapy is commonly used in HIV-1 infection, adverse effects from the combination of
      antiretrovirals and statins are possible. A more thorough understanding of the effects of
      statins on HIV-1 replication is essential to determine the potential therapeutic effect and
      to investigate the risks and benefits of this approach in vivo.

      We plan to conduct a double blind randomized placebo controlled trial, with a cross over
      design, to study the effects of atorvastatin in 22 HIV-infected patients not currently taking
      antiretroviral therapy. Patients will be randomized to receive either placebo or atorvastatin
      80mg for 8 weeks. After a 4-week wash out period patients on the atorvastatin arm will
      crossover to placebo and, vice versa patients in the placebo arm will cross over to
      atorvastatin for an additional 8 weeks. Upon completion of study medications all patients
      will be followed for 4 weeks. Each arm will have a minimum of 11 patients each. The primary
      outcome measure in this study is the effect of lipid lowering agents on HIV-1 RNA levels;
      additional secondary outcome measures include effects of lipid lowering agents on lipid
      profile, markers of inflammation and immune activation and investigations of host and viral
      genetic factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2006</start_date>
  <completion_date type="Actual">June 19, 2008</completion_date>
  <primary_completion_date type="Actual">June 19, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The change in HIV viral RNA level in plasma in response to lipid lowering agents was measured as log10 plasma RNA copy number, and the change in the log10 viral RNA level is included in table.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Cluster of Differentiation 4 (CD4+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>CD4+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 26 weeks.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>CD8+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+), CD8+(CD8+HLADR+CD38+) in Peripheral Blood</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>CD8+HLADR+CD38+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Atorvastatin, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg atorvastatin oral daily</description>
    <arm_group_label>Atorvastatin, then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Atorvastatin</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients will be administered placebo</description>
    <arm_group_label>Atorvastatin, then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Atorvastatin</arm_group_label>
    <other_name>no other name for placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Adults 18 years of age or older.

          -  Human Immunodeficiency Virus -1 (HIV-1) infection, as documented by a licensed
             Enzyme-Linked Immunosorbent Assay (ELISA) test kit and confirmed by a Western blot
             assay at any time point prior to study entry or at study entry (May do after informed
             consent if no test results are available).

        Off all antiretroviral (ARV) for greater than or equal to three months prior to study
        entry, no documented evidence of viral resistance, and no evidence of acute HIV infection.

          -  Willingness to use a method of contraception during the study period.

          -  Willingness to have blood drawn.

          -  No known allergy or contraindication to atorvastatin use.

          -  Ability to understand and willingness to sign the informed consent.

          -  Willingness to have blood stored for future phenotyping and genotyping.

          -  Cluster of differentiation 4 (CD4) cell count greater than 350 cells/ml.

          -  3 viral loads that average greater than 1000 copies/ml within a 4-week period.

          -  The viral loads will be done using the branched deoxyribonucleic acid (bDNA) method in
             the National Institutes of Health (NIH) laboratory and must be within 20% (log10bDNA
             of each other).

          -  A fasting total cholesterol lower than 240mg/dl and an Low-density lipoprotein (LDL)
             cholesterol lower than 130mg/dl.

          -  Liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT)) not greater than 1.5 times the upper limit of normal.

          -  Creatine phosphokinase elevations (CPK) not greater than 3 times the upper limit of
             normal (ULN) on two sequential determinations and, in the opinion of the investigator,
             without clear association with exercise.

          -  Laboratory values:

        Absolute neutrophil count (ANC) greater than or equal to 1000/mm(3).

        Hemoglobin greater than or equal to 11.0 g/dL.

        Platelet count greater than or equal to 100,000/mm(3).

        Creatinine less than or equal to 2 x ULN.

        Serum amylase and lipase less than or equal to 1.25 x ULN.

          -  Negative serum pregnancy test at randomization.

        EXCLUSION CRITERIA:

          -  Pregnancy or breast feeding.

          -  Active drug use or alcohol abuse/dependence, which in the opinion of the
             investigators, will interfere with the patient's ability to participate in the study.

          -  Serious illness requiring systemic treatment and/or hospitalization within 30 days of
             entry.

          -  Evidence of active opportunistic infections or neoplasms that require chemotherapy
             during the study period except cutaneous Kaposi Sarcoma.

          -  Allergy or hypersensitivity to atorvastatin or any of its components.

          -  History of myositis or rhabdomyolysis with use of any statins.

          -  History of inflammatory muscle disease such as poly or dermatomyositis.

          -  Concomitant use of fibric acid derivatives or other lipid lowering agents including
             patients on statins and Ezetimibe.

          -  Concomitant use of drugs that have significant interactions with atorvastatin. Please
             see appendix II for a listing.

          -  Concomitant use of St.Johns wort.

          -  Concomitant use of Valproic acid.

          -  Patients who are on concurrent immunomodulatory agents, including systemic
             corticosteroids, will be ineligible for 3 months after completion of therapy with the
             immunomodulating agents. Topical, nasal or inhaled corticosteroids use is not an
             exclusion criterion.

          -  Serum LDL cholesterol less than 40 mg/dl.

          -  Vaccinations within 6 weeks of study entry.

          -  Vaccinations within 6 weeks of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Maldarelli, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI), National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60.</citation>
    <PMID>9516219</PMID>
  </reference>
  <reference>
    <citation>Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000 Oct 21;356(9239):1423-30. Review.</citation>
    <PMID>11052597</PMID>
  </reference>
  <reference>
    <citation>Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19;353(9170):2093-9.</citation>
    <PMID>10382692</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2006</study_first_posted>
  <results_first_submitted>January 28, 2010</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2020</results_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Frank Maldarelli, M.D.</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Viremia</keyword>
  <keyword>Statin</keyword>
  <keyword>HIV Replication</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Lipid Raft</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>HIV Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2007</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT00367458/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Standard consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT00367458/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Screening consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT00367458/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin First, Then Placebo</title>
          <description>Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Atorvastatin</title>
          <description>Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention - 8 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period - 4-6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention - 8 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin First, Then Placebo</title>
          <description>Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Atorvastatin</title>
          <description>Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="B2" value="30" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="B3" value="30" lower_limit="21" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels</title>
        <description>The change in HIV viral RNA level in plasma in response to lipid lowering agents was measured as log10 plasma RNA copy number, and the change in the log10 viral RNA level is included in table.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels</title>
          <description>The change in HIV viral RNA level in plasma in response to lipid lowering agents was measured as log10 plasma RNA copy number, and the change in the log10 viral RNA level is included in table.</description>
          <units>Log10 copies/ml plasma</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.35" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.25" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Cluster of Differentiation 4 (CD4+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</title>
        <description>CD4+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Cluster of Differentiation 4 (CD4+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</title>
          <description>CD4+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
          <units>percent T cell subset</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CD4+HLA-DR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="5.34"/>
                    <measurement group_id="O2" value="0" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+HLA-DR+ at 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="5.05"/>
                    <measurement group_id="O2" value="-1.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Here is the count of participants with serious and non-serious adverse events. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 26 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Here is the count of participants with serious and non-serious adverse events. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</title>
        <description>CD8+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+) in Peripheral Blood</title>
          <description>CD8+HLA-DR+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
          <units>percent T cell subset</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CD8+HLA-DR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="10.28"/>
                    <measurement group_id="O2" value="0" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+HLA-DR+ at 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="8.80"/>
                    <measurement group_id="O2" value="-3.5" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+), CD8+(CD8+HLADR+CD38+) in Peripheral Blood</title>
        <description>CD8+HLADR+CD38+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Cluster of Differentiation 8 (CD8+) Human Leukocyte Antigen DR (HLA-DR+), CD8+(CD8+HLADR+CD38+) in Peripheral Blood</title>
          <description>CD8+HLADR+CD38+ are cellular markers of immune activation that is present in HIV infected individuals. This marker was measured before and after the statin/placebo intervention by standard lymphocyte phenotyping.</description>
          <units>percent T cell subset</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CD8+HLADR+CD38+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="12.31"/>
                    <measurement group_id="O2" value="0" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+HLADR+CD38+ at 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" spread="10.37"/>
                    <measurement group_id="O2" value="-3.3" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 26 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Patients were randomized to receive Atorvastatin for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients were randomized to receive placebo for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>low LDL</sub_title>
                <description>Due to concerns about the safety of intense lipid lowering in animal models, we established pre-specified LDL-c level (i.e., LDL-c&lt;40 mg/dl) for early termination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Treponema test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Supplementation therapy</sub_title>
                <description>Dietary supplement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank Maldarelli</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-435-8019</phone>
      <email>fmalli@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

